The invention discloses formulations for administration with pressurized
metered dose inhalers containing as active ingredient esters of
3,17-dihydroxy oestratriene derivatives, in solution in a
hydrofluorocarbon propellant, optionally one or more co-solvents, and
their use for the treatment of postmenopausal symptoms as well as of
menstrual migraine headaches.
